PRP11: EFFECTS OF DISEASE MANAGEMENT ON QUALITY OF LIFE IN PATIENTS WITH ASTHMA  by Greiner, W et al.
464 Abstracts
PRP9
COST-OF-ILLNESS STUDY OF PATIENTS WITH 
ALLERGIC ASTHMA AND SEASONAL ALLERGIC 
RHINITIS IN GERMANY
Quednau K1, Schramm B2, Ehlken B2, Smala A2, Naujoks C3, 
Berger K2
1Novartis Pharma GmbH, Nuremberg, Germany; 2MERG - 
Medical Economics Research Group, Munich, Germany; 
3Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: To evaluate the cost-of-illness of moder-
ate to severe allergic asthma and/or seasonal allergic rhin-
itis in Germany from the third-party payers’ and the pa-
tients’ perspective.
METHODS: Twenty pneumologists and 16 pediatricians
(office-based) participated. Five hundred patients (276
children) suffering from moderate to severe asthma and/
or seasonal allergic rhinitis (SAR) were included in this
retrospective, cross-sectional cost-of-illness study. Infor-
mation such as demographic characteristics, consulta-
tions, emergency visits, hospitalizations, rehabilitations,
out-of-pocket-expenditures such as OTC-medication, co-
payment or house refurbishment and absence from work
was collected with a standardized patient questionnaire.
Resource utilization of outpatient care was acquired from
305 patients’ records. Direct and indirect costs were con-
sidered.
RESULTS: Overall, annual costs per patient rise with
increasing severity of allergic asthma and in combina-
tion with seasonal allergic rhinitis. The average, annual,
per-patient cost for children with SAR is 3071 DEM
(€1566), for adolescents, 1509 DEM (€770), and for
adults, 2234 DEM (€1139). Annual per-patient costs
for severe asthma plus SAR increase to 14.431 DEM
(€7360) for children, to 17.059 DEM (€8700) for ado-
lescents, and to 18163 DEM (€9263) for an adult pa-
tient. From the third-party payers’ perspective, the main
cost drivers are medications, hospitalizations and rehabil-
itation. Additionally, around 6% of the adults retired
early due to asthma or asthma/SAR. From the patients’
perspective, house refurbishment was the most relevant
cost factor. For children and adolescents, direct costs are
responsible for 60 to 78% of the expenditures, whereas
for adults, the indirect costs are responsible for 58% of
the expenditures.
CONCLUSIONS: The financial burden due to allergic
asthma and/or seasonal allergic rhinitis from the third-
party payers’ perspective is comparable to other chronic
diseases such as coronary heart disease (CHD) or diabe-
tes mellitus type 2 in Germany. For patients, their rela-
tives and society, large additional costs accrue.
PRP10
VARIATIONS IN COVERAGE FOR EFFECTIVE 
SERVICES FOR ASTHMA: IMPACT OF
NATIONAL GUIDELINES
Hanlon JT, Wheeler J, Fendrick AM
University of Michigan, Ann Arbor, MI, USA
In 1997, the US National Institutes of Health issued the sec-
ond Guidelines for the Diagnosis and Management of
Asthma, to further improve the quality of care for asthma pa-
tients. Coverage of the interventions recommended in these
guidelines is imperative if optimal utilization is to occur.
OBJECTIVE: To quantify and compare coverage for
asthma services recommended by NIH guidelines among
statewide health-insurance plans.
METHODS: A survey of asthma services covered for the
year 2000 was administered to Quality Improvement
Managers of 28 managed care providers in the state of
Michigan. Management strategies included: inpatient and
outpatient hospital care; physician services; disease man-
agement services; patient education; prescription medica-
tions; medical devices, and emergency and urgent care
visits. Coverage was further delineated into private payer
benefits and Medicare (elderly) and Medicaid (poor) re-
cipients’ benefits. Additional data were collected via the
Internet on fee-for-service reimbursement rates.
RESULTS: Coverage of guideline-recommended services
varied within and among health plans. For example
Medicare emergency room visit coverage ranged from
20% of the facility costs to a $25 per visit charge. Alter-
natively, one provider offers variable rates for the same
service based on purchaser contract. Additionally, ser-
vices offered vary widely among plans. One facility of-
fered a fully implemented asthma case-management ser-
vice while another reported that no education or disease
management program was covered. The range of asthma-
care interventions supported by the health plans will be
fully described.
CONCLUSION: Significant variations in coverage exist
among health plans for asthma interventions. To ensure
optimal quality of care for asthma sufferers, health plans
should prioritize coverage for those interventions recom-
mended in evidence-based guidelines. Insurers and pro-
viders should examine and implement guidelines in order
to improve availability of proposed standards of asthma-
care management.
PRP11
EFFECTS OF DISEASE MANAGEMENT ON 
QUALITY OF LIFE IN PATIENTS WITH ASTHMA
Greiner W, Graf V.D. Schulenburg J-M, Blanke M
University of Hannover, Hannover, Germany
OBJECTIVES: This study deals with an economic evalu-
ation of a Disease Management Program for asthma with
the help of an electronic control instrument for Home-
Monitoring of the patient. Research was made on the im-
provement in quality of life as well as on the cost savings.
METHODS: One hundred twelve adult patients with
asthma of varying severities were divided randomly into
two groups. The patients are all members of a large Ger-
man health insurance group in the Bundesland Rhein-
land-Pfalz. The first group received an extensive Disease
Management Program with electronic Home-Monitor-
ing, while the control group was treated further by their
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GP. The patients were observed over a period of 12
months. Lung function tests and investigations on the
quality of life were carried out over three visits at inter-
vals of six months (at the beginning, after six months and
after 12 months). The quality of life was measured using
the Quality of Life Asthma (FLA) questionnaires, a vali-
dated disease-specific questionnaire and the EQ-5D (Euro-
Qol). In addition, the treatment costs during the study time
period were documented and evaluated.
RESULTS: During the study, the quality of life of the
control group revealed no changes statistically, while the
patients in the disease management group achieved sig-
nificantly higher values than those at the beginning of the
study. The improvements are related particularly to the
“Physical and Psychic Attributes” of the FLA, although
they can also be seen in the (less sensitive) generic EQ-5D.
Thus, the average EQ-5D value of 62 increased to 72,
while in the control group it dropped from 65 to 60. The
study data additionally shows that considerable savings
are possible with disease management for asthma, espe-
cially concerning hospital services. These savings are
partly counteracted with higher costs in other areas, par-
ticularly medication.
CONCLUSIONS: Disease management for asthma can
lead to an improvement of the patient’s quality of life and
a reduction in treatment costs.
PRP12
ASTHMA KNOWLEDGE AND QUALITY OF LIFE 
(QOL) OF ADULT ASTHMATICS
Meszaros A1, Vincze G2, Mesko A1,Orosz DM1
1Semmelweis University, Budapest, Hungary; 2University of 
Texas at Austin, Austin, TX, USA
OBJECTIVE: Good asthma knowledge and compliance
with treatment are critical factors for the success of any
asthma management plan. The purpose of the study was
to examine the QoL with the St. George’s Respiratory
Questionnaire (SGRQ) and a visual analogue scale (VAS).
We developed a short educational program based on the
WHO-EuroPharm Forum Guidelines and assessed its ef-
fectiveness by using a short questionnaire.
METHODS: We selected 32 asthmatics (mean age:
39,75; range: 14,57) with long asthma history. Patients’
QoL was assessed twice, before and three month after an
educational seminar. The results of the two assessments
were analyzed using SPSS statistical software.
RESULTS: On the VAS, in which a score of 100 repre-
sents perfect health, patients’ scores by severity were:
mild—first visit 81.72, second 82.83; moderate—first
visit 69.14, second 69.14. On SGRQ, where high scores
represent worse health status the scores at the first visit
for mild patients were: symptom 150.08; activity 367.47;
impact 399.56; total 917.12. In moderate patients the
scores were: symptom 259.41; activity 501.43; impact
514.37; total 1275.23. At the second visit, scores for mild
patients were: symptom 172.50; activity 339.07; impact
342.20; total 853.78. Moderate patients scored: symp-
tom 282.36; activity 506.28; impact 485.89; total
1274.53. We found 30% improvement in asthma knowl-
edge (p  .01). There were no significant changes in tech-
niques for use of inhalers. The number of patients using a
peak flow meter increased from 15% to 28% and all
were using it correctly and regularly.
CONCLUSIONS: QoL scores did not change substan-
tially, although a slight improvement occurred in the ac-
tivity, impact, and total scores in the mild group. As these
patients were regularly controlled, we expected better
knowledge of general asthma and inhaler use technique.
We can conclude that it is necessary to refresh asthma
knowledge regularly. It is also important to regularly as-
sess patients’ self-management plans by aiming to in-
crease their effectiveness.
PRP13
IMPACT OF ACUTE EXACERBATIONS OF 
CHRONIC BRONCHITIS (AECB) IN FRANCE
Duprat-Lomon I1, Mortier N1, Blin P2, Chevallier E2, Sagnier PP3
1Bayer Pharma, Puteaux, France; 2Icare, Massy, France; 3Bayer 
Plc, Slough, UK
OBJECTIVE: The aim of this study was to define the
main characteristics of patients presenting with an AECB
in general practice.
METHODS: This cross-sectional study was performed
by a representative sample of 120 General Practitioners
(GPs), selected by random pooling from a national data-
base. Each GP was required to recruit prospectively and
consequently a maximum of eight patients aged 35 years
or more with AECB defined by at least one of the Antho-
nisen criteria. Socio-demographics, medical history of
chronic bronchitis and the current episode management
were collected. The Saint-George’s Respiratory Question-
naire (SGRQ) was self-administered by the patients.
RESULTS: One hundred one GPs recruited 417 patients
from November 2000 to April 2001. The patients were
on average 65 years old, with 67% over 60 years.
Twenty nine percent (121) of patients were smokers and
163 (40%) were former smokers. They had been suffer-
ing from chronic bronchitis for an average of 13 years.
During the last 12 months, 351 patients (85%) experi-
enced four or less episodes of AECB (mean  3 episodes),
and 52 patients (12%) were hospitalized due to the dis-
ease. FEV1 was available for 186 patients. The value was
greater than 80% for 14% of the patients, between 35%
and 80% for 76%, and less than 35% for 10%. Most of
the patients were classified as Anthonisen 1 (289 pa-
tients, 69%), and 104 patients (25%) as Anthonisen 2.
The total mean score from the SGRQ was 54 (n  275)
(symptoms 62, activity 63, impact 46) and consistently
increased with age, duration of chronic bronchitis, FEV1,
number of AECB episodes and Anthonisen severity.
CONCLUSION: This observational study confirmed the
importance of risk factors and the severity of AECB in
patients managed by GPs, with significant burden of dis-
ease.
